Effectiveness of Conservative Treatment on Chronic Venous Disease Symptoms and Quality of Life in Patients with Type 2 Diabetes: Results from a Subanalysis of the VEIN STEP Observational Study
Open Access
- 1 February 2026
- journal article
- research article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 22, 1-13
Abstract
Background: This post-hoc subanalysis of the VEIN STEP study assessed the effectiveness of conservative treatment, particularly venoactive drugs (VAD), in reducing chronic venous disease (CVD) signs and symptoms and improving quality of life (QoL) for patients with type 2 diabetes (T2D) in a real-life setting. Methods: VEIN STEP was an observational, prospective study conducted in adult outpatients who consulted for symptomatic CVD (NCT04574375). CVD symptoms (10-cm Visual Analog Scale and Patient Global Impression of Change), disease severity (Venous Clinical Severity Score), and QoL (Chronic Venous Insufficiency Questionnaire [CIVIQ-14]) were assessed. Results: Overall, 6084 patients were analyzed, of whom 702 (11.5%) had T2D. These patients were more likely to be older, present with a more advanced CEAP class, have a higher body mass index, greater symptom severity and reduced QoL scores than those without T2D (p< 0.001 for all). Almost all patients with T2D (97.3%) received VAD-based treatment, mainly micronized purified flavonoid fraction (MPFF, 72.2%) or diosmin (24.6%). After 4 weeks, conservative therapy was associated with significant improvements in CVD symptoms and QoL (p< 0.001). Physicians also noted a significant improvement in disease severity (p< 0.001). The decrease in global symptom intensity was significantly greater among patients treated with MPFF than in those treated with diosmin (mean − 2.7± 1.8 vs − 2.0± 1.8, p=0.004). Greater reductions in symptom intensity were also observed in patients treated with MPFF for pain (p=0.011), leg heaviness (p=0.006), and swelling (p=0.014), with a tendency for greater improvement of cramps. QoL improved for patients receiving MPFF and those receiving diosmin, with changes in CIVIQ-14 global index score of − 21.3± 15.8 and − 15.5± 14.6, respectively. Conclusion: These findings indicate that patients with concomitant CVD and T2D are more likely to have greater symptom severity and disease burden. In such patients, VAD-based conservative therapy, particularly MPFF, was associated with significant improvements in CVD-related symptoms and QoL. Plain Language Summary: Chronic venous disease (CVD) is a common condition that often coexists with type 2 diabetes (T2D), with which it shares many risk factors such as aging, obesity, and inactive lifestyles. The VEIN STEP observational study included over 6,000 patients with CVD, 11.5% of whom also had T2D. Subjects with both conditions had worse symptoms, more severe disease, and lower quality of life than those with CVD alone. For the majority, interventions consisted of non-surgical treatments such as compression therapy and venoactive drugs, especially micronized purified flavonoid fraction (MPFF) and diosmin. There is a strong connection between CVD and T2D and the presence of one condition should prompt physicians to examine the patient for the other. This study shows that early diagnosis and treatment can significantly reduce CVD symptoms and improve quality of life. It also calls for more attention to managing CVD in people with T2D to reduce complications and improve outcomes.Keywords
This publication has 44 references indexed in Scilit:
- VEIN STEP: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous DiseaseAdvances in Therapy, 2023
- Quality of Life in Chronic Venous Disease: Bridging the Gap Between Patients and PhysiciansClinical Drug Investigation, 2023
- Dietary Effects on Chronic Venous DiseaseAnnals of Vascular Surgery, 2022
- Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th editionDiabetes Research and Clinical Practice, 2019
- The Seriousness of Chronic Venous Disease: A Review of Real-World EvidenceAdvances in Therapy, 2019
- Micronized Purified Flavonoid Fraction (MPFF) for Patients Suffering from Chronic Venous Disease: A Review of New EvidenceAdvances in Therapy, 2019
- Protective Effects of Micronized Purified Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous HypertensionEuropean Journal of Vascular and Endovascular Surgery, 2018
- Psychometric Validation of the 14 items ChronIc Venous Insufficiency Quality of Life Questionnaire (CIVIQ-14): Confirmatory Factor AnalysisEuropean Journal of Vascular and Endovascular Surgery, 2016
- Diabetes mellitus is associated with early chronic venous disorder of the lower extremities in Chinese patients with cardiometabolic risk factorsDiabetes/Metabolism Research and Reviews, 2014
- Construction and international validation of CIVIQ-14 (a short form of CIVIQ-20), a new questionnaire with a stable factorial structureQuality of Life Research, 2011